Does the media refer more to SMMT or RCUS?

In the previous week, Summit Therapeutics had 18 more articles in the media than Arcus Biosciences. MarketBeat recorded 20 mentions for Summit Therapeutics and 2 mentions for Arcus Biosciences. Summit Therapeutics' average media sentiment score of 0.42 beat Arcus Biosciences' score of 0.35 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Arcus Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RCUS or MDGL?

In the previous week, Arcus Biosciences and Arcus Biosciences both had 2 articles in the media. Madrigal Pharmaceuticals' average media sentiment score of 0.57 beat Arcus Biosciences' score of 0.35 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Madrigal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RCUS or BMRN?

In the previous week, BioMarin Pharmaceutical had 7 more articles in the media than Arcus Biosciences. MarketBeat recorded 9 mentions for BioMarin Pharmaceutical and 2 mentions for Arcus Biosciences. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat Arcus Biosciences' score of 0.35 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioMarin Pharmaceutical 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KRYS or RCUS?

In the previous week, Krystal Biotech and Krystal Biotech both had 2 articles in the media. Arcus Biosciences' average media sentiment score of 0.35 beat Krystal Biotech's score of 0.25 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcus Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KYMR or RCUS?

In the previous week, Kymera Therapeutics had 2 more articles in the media than Arcus Biosciences. MarketBeat recorded 4 mentions for Kymera Therapeutics and 2 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.35 beat Kymera Therapeutics' score of 0.34 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcus Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Arcus Biosciences (RCUS) Competitors

$24.43 -0.80 (-3.19%)

Closing price 03:59 PM Eastern

Extended Trading

$24.51 +0.08 (+0.34%)

As of 07:30 PM Eastern

Compare

RCUS vs. SMMT, MDGL, BMRN, KRYS, and KYMR

Should you buy Arcus Biosciences stock or one of its competitors? Arcus Biosciences's main competitors and comparable companies include Summit Therapeutics (SMMT), Madrigal Pharmaceuticals (MDGL), BioMarin Pharmaceutical (BMRN), Krystal Biotech (KRYS), and Kymera Therapeutics (KYMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arcus Biosciences compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Arcus Biosciences has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Arcus Biosciences	$247M	12.63	-$353M	-$3.90	N/A

Summit Therapeutics has a beta of -1.51, suggesting that its stock price is 251% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Summit Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Arcus Biosciences' return on equity of -89.54% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

Summit Therapeutics presently has a consensus target price of $28.61, suggesting a potential upside of 70.84%. Arcus Biosciences has a consensus target price of $38.30, suggesting a potential upside of 56.28%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Summit Therapeutics had 18 more articles in the media than Arcus Biosciences. MarketBeat recorded 20 mentions for Summit Therapeutics and 2 mentions for Arcus Biosciences. Summit Therapeutics' average media sentiment score of 0.42 beat Arcus Biosciences' score of 0.35 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Arcus Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Arcus Biosciences beats Summit Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Madrigal Pharmaceuticals?

Arcus Biosciences (NYSE:RCUS) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Arcus Biosciences has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, indicating that its share price is 204% less volatile than the broader market.

In the previous week, Arcus Biosciences and Arcus Biosciences both had 2 articles in the media. Madrigal Pharmaceuticals' average media sentiment score of 0.57 beat Arcus Biosciences' score of 0.35 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals has a net margin of -25.32% compared to Arcus Biosciences' net margin of -393.16%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Madrigal Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.63	-$353M	-$3.90	N/A
Madrigal Pharmaceuticals	$958.40M	11.90	-$288.28M	-$12.89	N/A

Arcus Biosciences presently has a consensus target price of $38.30, suggesting a potential upside of 56.28%. Madrigal Pharmaceuticals has a consensus target price of $710.20, suggesting a potential upside of 43.79%. Given Arcus Biosciences' higher possible upside, equities analysts plainly believe Arcus Biosciences is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Madrigal Pharmaceuticals beats Arcus Biosciences on 10 of the 15 factors compared between the two stocks.

How does Arcus Biosciences compare to BioMarin Pharmaceutical?

Arcus Biosciences (NYSE:RCUS) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

In the previous week, BioMarin Pharmaceutical had 7 more articles in the media than Arcus Biosciences. MarketBeat recorded 9 mentions for BioMarin Pharmaceutical and 2 mentions for Arcus Biosciences. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat Arcus Biosciences' score of 0.35 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioMarin Pharmaceutical	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcus Biosciences presently has a consensus target price of $38.30, suggesting a potential upside of 56.28%. BioMarin Pharmaceutical has a consensus target price of $89.17, suggesting a potential upside of 55.71%. Given Arcus Biosciences' higher probable upside, equities research analysts clearly believe Arcus Biosciences is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.67

BioMarin Pharmaceutical has a net margin of 2.14% compared to Arcus Biosciences' net margin of -393.16%. BioMarin Pharmaceutical's return on equity of 5.32% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Arcus Biosciences has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market.

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioMarin Pharmaceutical has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.63	-$353M	-$3.90	N/A
BioMarin Pharmaceutical	$3.22B	3.44	$348.90M	$0.37	154.79

Summary

BioMarin Pharmaceutical beats Arcus Biosciences on 13 of the 17 factors compared between the two stocks.

How does Arcus Biosciences compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Arcus Biosciences (NYSE:RCUS) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Krystal Biotech presently has a consensus price target of $377.20, indicating a potential upside of 15.72%. Arcus Biosciences has a consensus price target of $38.30, indicating a potential upside of 56.28%. Given Arcus Biosciences' higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Krystal Biotech has a net margin of 54.82% compared to Arcus Biosciences' net margin of -393.16%. Krystal Biotech's return on equity of 19.34% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

Krystal Biotech has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Krystal Biotech has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	24.79	$204.83M	$7.98	40.85
Arcus Biosciences	$247M	12.63	-$353M	-$3.90	N/A

In the previous week, Krystal Biotech and Krystal Biotech both had 2 articles in the media. Arcus Biosciences' average media sentiment score of 0.35 beat Krystal Biotech's score of 0.25 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Krystal Biotech beats Arcus Biosciences on 11 of the 15 factors compared between the two stocks.

How does Arcus Biosciences compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Arcus Biosciences (NYSE:RCUS) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Kymera Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Kymera Therapeutics has a net margin of -285.33% compared to Arcus Biosciences' net margin of -393.16%. Kymera Therapeutics' return on equity of -21.22% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

In the previous week, Kymera Therapeutics had 2 more articles in the media than Arcus Biosciences. MarketBeat recorded 4 mentions for Kymera Therapeutics and 2 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.35 beat Kymera Therapeutics' score of 0.34 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kymera Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	230.96	-$311.35M	-$3.24	N/A
Arcus Biosciences	$247M	12.63	-$353M	-$3.90	N/A

Kymera Therapeutics presently has a consensus price target of $133.21, indicating a potential upside of 22.31%. Arcus Biosciences has a consensus price target of $38.30, indicating a potential upside of 56.28%. Given Arcus Biosciences' higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

92.9% of Arcus Biosciences shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Kymera Therapeutics beats Arcus Biosciences on 12 of the 17 factors compared between the two stocks.

Get Arcus Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCUS vs. The Competition

Export

Metric	Arcus Biosciences	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$3.21B	$3.87B	$7.14B	$22.65B
Dividend Yield	N/A	3.65%	2.54%	3.73%
P/E Ratio	-6.26	12.93	273.67	27.75
Price / Sales	12.59	1,308.36	612.51	21.37
Price / Cash	N/A	122.60	77.60	38.88
Price / Book	4.18	16.63	10.92	4.64
Net Income	-$353M	-$22.67M	$3.50B	$1.08B
7 Day Performance	-1.97%	-3.05%	-2.11%	-1.06%
1 Month Performance	-18.53%	-10.75%	-6.34%	-5.03%
1 Year Performance	82.53%	21.11%	8.81%	5.78%

Arcus Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCUS Arcus Biosciences	2.8893 of 5 stars	$24.43 -3.2%	$38.30 +56.8%	+86.9%	$3.21B	$247M	N/A	601	Analyst Forecast
SMMT Summit Therapeutics	2.8723 of 5 stars	$15.48 -0.8%	$27.07 +74.9%	-18.5%	$12.45B	N/A	N/A	265	Analyst Forecast
MDGL Madrigal Pharmaceuticals	3.0007 of 5 stars	$517.04 +0.1%	$710.20 +37.4%	+11.3%	$11.93B	$958.40M	N/A	915
BMRN BioMarin Pharmaceutical	4.4491 of 5 stars	$59.46 -1.3%	$89.17 +50.0%	+6.5%	$11.66B	$3.22B	160.70	3,221	Trending News
KRYS Krystal Biotech	4.3034 of 5 stars	$337.08 -2.5%	$377.20 +11.9%	+81.1%	$10.24B	$389.13M	42.24	295

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RCUS) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcus Biosciences (RCUS) Competitors

RCUS vs. SMMT, MDGL, BMRN, KRYS, and KYMR

How does Arcus Biosciences compare to Summit Therapeutics?

Summary

How does Arcus Biosciences compare to Madrigal Pharmaceuticals?

Summary

How does Arcus Biosciences compare to BioMarin Pharmaceutical?

Summary

How does Arcus Biosciences compare to Krystal Biotech?

Summary

How does Arcus Biosciences compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcus Biosciences (RCUS) Competitors

RCUS vs. SMMT, MDGL, BMRN, KRYS, and KYMR

How does Arcus Biosciences compare to Summit Therapeutics?

Which has better earnings & valuation, SMMT or RCUS?

Which has more risk & volatility, SMMT or RCUS?

Is SMMT or RCUS more profitable?

Do analysts recommend SMMT or RCUS?

Does the media refer more to SMMT or RCUS?

Do insiders and institutionals hold more shares of SMMT or RCUS?

Summary

How does Arcus Biosciences compare to Madrigal Pharmaceuticals?

Which has more volatility & risk, RCUS or MDGL?

Does the media prefer RCUS or MDGL?

Is RCUS or MDGL more profitable?

Which has better valuation and earnings, RCUS or MDGL?

Do analysts recommend RCUS or MDGL?

Do institutionals & insiders hold more shares of RCUS or MDGL?

Summary

How does Arcus Biosciences compare to BioMarin Pharmaceutical?

Does the media refer more to RCUS or BMRN?

Do analysts prefer RCUS or BMRN?

Is RCUS or BMRN more profitable?

Which has more risk & volatility, RCUS or BMRN?

Do insiders & institutionals believe in RCUS or BMRN?

Which has better earnings & valuation, RCUS or BMRN?

Summary

How does Arcus Biosciences compare to Krystal Biotech?

Do analysts prefer KRYS or RCUS?

Is KRYS or RCUS more profitable?

Which has more volatility and risk, KRYS or RCUS?

Do insiders and institutionals have more ownership in KRYS or RCUS?

Which has stronger valuation and earnings, KRYS or RCUS?

Does the media prefer KRYS or RCUS?

Summary

How does Arcus Biosciences compare to Kymera Therapeutics?

Which has more risk and volatility, KYMR or RCUS?

Is KYMR or RCUS more profitable?

Does the media refer more to KYMR or RCUS?

Which has better valuation & earnings, KYMR or RCUS?

Do analysts rate KYMR or RCUS?

Do insiders and institutionals believe in KYMR or RCUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools